SCHEDULE 13G/A: BlackRock Discloses 4.1% Passive Stake in Inozyme Pharma
Beneficial Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.1% beneficial ownership stake in Inozyme Pharma Inc. as of June 30, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 2,663,678 shares of Inozyme Pharma Inc. common stock.
- This ownership represents 4.1% of the total outstanding common stock of Inozyme Pharma Inc.
- BlackRock holds sole voting power and sole dispositive power over all 2,663,678 shares.
- The filing is an Amendment No. 1 to Schedule 13G, indicating a change to a previously reported passive investment.
- The event date requiring this filing is stated as June 30, 2025.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Inozyme Pharma Inc.
Sentiment
Score: 5
Explanation: Neutral, as this is a routine regulatory disclosure of passive ownership and does not contain performance or strategic updates from the issuer.
Future Outlook
NA
Industry Context
Schedule 13G filings are routine disclosures by institutional investors like BlackRock when their beneficial ownership in a company's stock exceeds 5% (initial filing) or when there are changes to previously reported stakes, indicating a passive investment intent. This filing shows BlackRock's continued or adjusted passive investment in Inozyme Pharma Inc., reflecting a standard portfolio holding rather than an active strategic move.
Stakeholder Impact
- Shareholders of Inozyme Pharma Inc. are informed of BlackRock's passive investment stake, which may provide a degree of institutional validation.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney revoked by BlackRock, Inc. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 2025-06-30 | Date of event which requires filing of this statement for BlackRock's beneficial ownership in Inozyme Pharma Inc. |
| 2025-07-17 | Signature date of the Schedule 13G filing by BlackRock, Inc. |
Keywords
BlackRock, Inozyme Pharma Inc., Schedule 13G, beneficial ownership, common stock, institutional investment, passive stake, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.